RE: p&d7 Oct 2022 13:17
Why would a Director have bought a couple of weeks ago if he didn't think the case was watertight?
26 September 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces that, in addition to the Director Dealing announced on 16 September 2023 (https://polaris.brighterir.com/public/abingdon_health/news/rns/story/w6zdykr), on 23 September 2022, Chris Yates, Chief Executive Officer purchased a total of 125,000 ordinary shares of 0.25 pence each ("Ordinary Shares") over two trades (the "Purchases") at a price of 7.3 pence per Ordinary Share. Further to the Purchases, the interest of Chris Yates in the Company is as follows:
Director
Previous number of Ordinary Shares held
Number of Ordinary Shares Purchased
Number of Ordinary Shares held following Purchases
Percentage of Ordinary Shares held following Purchases
Chris Yates
7,763,844
125,000
7,888,844
6.48%